The protein tyrosine kinase (PTK) receptors and cytosolic signaling proteins as well as the protein tyrosine phosphatases (PTPs) have important roles in regulation of growth of the benign and malignant prostate gland. Here we studied expression of the protein tyrosine phosphatase SHP-1 in prostate cancer cell lines and in human prostatic tissues. SHP-1 is expressed at a high level in LNCaP prostate cancer cells compared with PC3 cells.
Introduction
Prostate cancer is one of the most frequent cancers in males in Western countries 1 .
Prostate-specific antigen (PSA) is used widely as a marker in initial diagnosis of prostate cancer and for monitoring the response to treatment. Radical prostatectomy (RP) serves as the first line of treatment for patients with localized prostate cancer 2 . However, in many cases the cancer will recur, as evidenced by rising levels of serum PSA, a phenomenon known as biochemical recurrence (BCR). This is an important concern and it is currently difficult to identify those patients at a high risk of tumor recurrence 3 . There are very few biomarkers that can be used to differentiate aggressive from non-aggressive tumors after diagnosis. Thus, molecular markers associated with and predicting disease recurrence are needed to help identify patients with an increased risk of developing tumor recurrence despite efficient local therapy.
Phosphorylation of proteins at specific tyrosine residues has an important role in regulating cell proliferation in multiple aspects of oncogenesis. The level of tyrosine phosphorylation of cellular proteins is controlled by protein tyrosine kinases (PTKs) and the level of dephosphorylation by protein tyrosine phosphatases (PTPs) 4 . Extensive studies have been performed to determine the role of PTKs in carcinogenesis and growth regulation. For example, Src-related kinases have been reported to have increased activity or expression levels in several malignancies including prostate cancer 5, 6 . It has been
shown that inhibition of Src activation causes cell cycle arrest and reduces cell migration and cell growth in prostate cancer 7 . The epidermal growth factor receptor (EGFR) has also been shown to be upregulated in prostate cancer 8 . This receptor can be targeted with monoclonal antibodies or with tyrosine kinase inhibitors, suppressing the growth and invasion of androgen-dependent and -independent prostate cancer cells in vitro 9, 10 The functional roles of PTPs in human cancer are, however, much less well understood.
The Src-homology PTP SHP-1 is a non-receptor phosphatase that contains two SH2
domains at its N-terminus, a single catalytic domain, and a C-terminal tail that contains tyrosine residues 11 . SHP-1 is expressed in normal hematopoietic and epithelial cells.
Decreased or abolished expression in leukemia and lymphoma has been related to both malignant transformation and tumor cell invasiveness [12] [13] [14] . Moreover, SHP-1 expression in leukemic cells can lead to decreased proliferation and induction of morphological changes 15 . Transient transfection of SHP-1 in the breast cancer cell line MDA-MB-231, with undetectable endogenous SHP-1, reduced cell proliferation 2-3 fold 16 . Zapata et al. 17 have detected SHP-1 expression in the normal human prostate as well as in prostate cancer and they showed evidence of decreased SHP-1 expression in prostate cancer. SHP-1 has been shown to be involved in regulating signals of cytokines such as IL-3R in leukemic cells, PDGF-and EGF receptor and other tyrosine kinase receptors in non-hematopoietic cells [18] [19] [20] .
Interleukin-6 (IL-6) is a cytokine that has been implicated in the development and progression of several types of tumors including those in the prostate 21 . The expression of IL-6 and its receptor has been shown in human prostate cancer cell lines and in clinical specimens of prostate cancer and benign prostate hyperplasia 22 . High levels of IL-6 are observed in the plasma of patients with prostate cancer, which correlate with more 5 advanced stages of the disease, therapy resistance 23 , and poor prognosis 24 . In in vitro experiments IL-6 has been reported to affect cell proliferation and to induce neuroendocrine (NE) differentiation [25] [26] [27] [28] of prostate cancer cells in a complicated manner depending on autocrine or paracrine cytokine action [27] [28] [29] . IL-6 binds to its receptor and mainly transduces signals through MAP kinase/ERK, PI3K/AKT and STAT3 pathways 30 .
It has been shown in oligodendrocytes from the motheaten mice, which have a genetic defect in the SHP-1 gene, that SHP-1 expression controls the activation of STAT3 by IL-6 signaling 31 .
In this study we examined SHP-1 in prostate cancer cell lines and in clinically well- 
Material and Methods

Cell cultures
The 
cDNA microarray
Gene expression levels in PC3 and LNCaP cells were analyzed by using an Illumina
Beadchip cDNA microarray. In brief, total RNA from cells was extracted, utilizing a two- BeadStudio software (Illumina).
Western Blotting
Cells were lysed with ice-cold lysis buffer: 9 mM Hepes, 0.08 mM EDTA, 0.08 mM EGTA, 9 mM KCL, 5% NP-40 and complete protease inhibitor (Roche, Mannheim.
Germany) at 4 °C for 10 min. The samples were centrifuged for 15 min at 16 000 × g at 4
°C and the supernatants were collected. Protein concentrations were determined by using a BCA protein assay (Pierce Biotechnology, Inc., Rockford USA). Thirty µg of each protein sample was subjected to 10% SDS-PAGE and transferred to PVDF membranes 
Cell cycle analysis by flow cytometry
The effect of SHP-1 on cells entering the S-phase of the cell cycle was determined by flow cytometry. PC3 and LNCaP cells were plated in 6 cm plates (Sarstedt, Germany), serum-starved overnight and then transfected with either pEGFP plasmids, pEGFP-SHP1-WT plasmids or SHP-1 siRNA (Dharmacon, Thermo Fisher Scientific) using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 24 h, FCS was added to the medium (10%). The cells were washed with PBS and fixed in ice-cold 70% ethanol for 15 min. After treatment with RNase A (100 µg/ml), propidium iodide (50 µg/ml) and 0.05% Triton X-100 for 30 min, the number of cells in the S-phase was analyzed by using a FACS Calibur flow cytometer (BD Bioscience, New Jersey, USA).
Prostate cancer tissue microarray analysis
The were alive. Twenty of the 100 patients in whom SHP-1 could be evaluated had a BCR during the follow-up period and 25 showed progression of the disease.
Tissue microarrays were constructed as described previously 32 . In brief, areas representing cancer as well as normal prostate tissue were marked on hematoxylin/eosinstained sections and two 1.00 mm tissue cores were extracted and mounted using a manual arraying device (MTA-1 Beecher Instruments Inc., Sun Prairie, WI).
Immunohistochemical (IHC) staining of SHP-1 was performed with a polyclonal anti- (Fig. 1a) . The difference in expression was confirmed at the protein level, using both immunocytochemistry and
Western blot analysis (Fig. 1b) .
Functional analysis of SHP-1 in prostate cancer cell lines
To investigate whether SHP-1 affects proliferation in prostate cancer cells, we inhibited h in case of stably-transfected PC3 cells (Fig. 2a) . The SHP-1 siRNA-treated LNCaP cells showed a higher proliferation rate than the controls that were transfected with a scrambled control siRNA. Interestingly, in both the transient as well as the stably-transfected PC3 cells, the proliferation rate was decreased in comparison with control cells. Western blot analysis was performed to confirm successful overexpression or knock-down of SHP-1 (Fig. 2b) . Indeed, SHP-1 siRNA treatment of LNCaP cells reduced SHP-1 expression, whereas overexpression of SHP-1 was demonstrated in PC3 cells. To confirm the proliferation data we stained the cells with propidium iodide to perform cell cycle analysis using flow cytometry (Fig. 2c) . The analysis showed that more cells entered the S-phase in siRNA-treated LNCaP cells than in parental or siControl RNA-treated cells, whereas upon overexpression of SHP-1 in PC3 cells the number of cells that entered the S-phase was reduced. To understand the mechanism underlying the growth arrest and proliferation in siRNA-treated LNCaP and SHP-1-overexpressing PC3 cells we analysed the level of cyclin D1 protein that regulates G1 to S phase progression of the cell cycle (Fig. 2d) . The cells were treated with serum for 6 and 24 h, and indeed cyclin D1 expression was stronger in siRNA-treated LNCaP cells than in control cells, whereas in SHP-1-overexpressing PC3 cells the cyclin D1 levels were decreased when compared to the control.
IL-6 stimulation of prostate cancer cell lines
Since IL-6 has been implicated to be involved in the development and progression of prostate cancer, we studied whether SHP-1 is involved in the response of LNCaP and PC3
cells to IL-6 stimulation. As shown previously 33 , LNCaP cells showed a growth inhibitory response to IL-6, whereas in PC3 cells IL-6 had a growth stimulatory response (Fig. 3a) .
Because SHP-1 is a phosphatase that is involved in modulation of receptor signaling, we also analyzed the IL-6 response in SHP-1 siRNA-treated LNCaP cells, and SHP-1 overexpressing PC3 cells. In LNCaP cells, silencing SHP-1 expression did not affect the growth inhibitory response to IL-6, whereas in PC3 cells, overexpressing SHP-1 abolished the growth stimulatory response to IL-6 (Fig. 3b) . Since SHP-1 has been implicated to have a role in activation of STAT3 by IL-6 we analyzed the phosphorylation status of STAT3 after IL-6 treatment in LNCaP cells. Indeed, the siRNA-treated LNCaP cells showed increased levels of phosphorylated STAT3 compared to siControl-treated cells (Fig 3c) . Because PC3 cells do not express endogenous STAT3 protein (data not shown) they were not analyzed for phosphorylated STAT3 levels.
SHP-1 expression in prostate cancer
Analysis of SHP-1 expression in prostate cancer tissue revealed that SHP-1 immune reactivity was localized to the cytoplasm of prostate epithelial cells and the tumor cells that were stained for SHP-1. Expression of SHP-1 could be evaluated in 100 cases -the remaining cases were not available for analysis owing to core loss during sectioning and staining. Staining was strong in normal epithelial cells, whereas in tumor cells staining intensity was heterogeneous, varying from absent to strong. Representative photomicrographs are shown in Figure 4 . Nine of the cores showed no staining, thirtythree had weak staining, fifty had a moderate staining and eight showed strong staining.
No staining was seen in stromal cells but occasionally we found infiltrating cells of hematopoietic origin in the stromal compartment, with strong immunoreactivity towards SHP-1.
Correlation of SHP-1 with PSA and clinicopathological parameters
We used statistical analyses to assess the potential association of the intensity of SHP-1 expression with preoperative levels of serum PSA, Gleason grades and other tumor characteristics. Expression of SHP-1 was dichotomized into high (scores 2 & 3) and low (scores 0 & 1). In Spearman's rank analysis we found no statistically significant correlations between SHP-1 expression and preoperative PSA levels (p=0.835; Fig. 5a ),
Gleason scores (p=0.857; Fig. 5b ), tumor volume (p=0.082; Fig. 5c ) or prostate volume (p=0.243; Fig. 5d ).
Survival analysis
A postoperative rise in serum PSA levels (biochemical recurrence, BCR), defined as a PSA concentration >0.2 ng/ml in blood, with a confirmatory value, is widely used to monitor the outcome of radical prostatectomy. We investigated whether or not SHP-1 expression was correlated to clinical outcome, using BCR-free time and clinical progression-free time as primary endpoints. Twenty of the 100 (20%) patients in whom SHP-1 could be evaluated experienced BCR during the follow-up period and twenty-five (25%) showed disease progression.
As shown in Figure 6 , patients with low levels of tumor-specific SHP-1 expression in prostatectomy specimens had a significantly poorer outcome with respect to BCR and Table 2 ).
Discussion
Here we have shown that the PTP SHP-1 is expressed at a high level in normal prostate tissue and is commonly decreased to a low or non-detectable level in prostate cancer. Most importantly, decreased levels of SHP-1 were associated with a significantly shorter time to biochemical recurrence and clinical progression after radical prostatectomy for localized prostate cancer.
In an attempt to define the functional role of SHP-1 in prostate cancer, we used the prostatic cancer cell lines LNCaP and PC3, which express SHP-1 mRNA and protein at relatively high and low levels, respectively. We showed that inhibition of SHP-1 expression with siRNA resulted in increased cellular proliferation, whereas overexpression decreased the proliferation rate. These results suggest that SHP-1 has an important role in and/or other substrates such as JAK 38, 39 . It is possible that SHP-1 regulates the JAK/STAT signaling transduction pathway via this mechanism, leading to a decrease in proliferative signals [38] [39] [40] . SHP-1 has also been shown to be associated with epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR) and interleukin-3 receptor (IL-3R) in epithelial cells [18] [19] [20] 40 , thereby possibly modulating cell signaling. EGFR is involved in the pathogenesis of several types of tumor 41 and both EGF and EGFR are frequently upregulated in advanced stages of prostate cancer 8 . Activated EGFR pathways are considered to belong to mechanisms that take over upon development of androgen resistance [42] [43] [44] . Similarly, the IL-6 pathway has been suggested to play an important role in the development and growth of androgen-independent prostate cancer 45 .
As shown before by others [46] [47] [48] we also found that a short term treatment with IL-6 inhibits growth of androgen-responsive LNCaP cells, whereas in androgen-unresponsive PC3 cells it evokes a growth stimulatory effect. We then analyzed how SHP-1 expression affects the IL-6 response in these cell lines. We show that the response to IL-6 was not In prostate cancer, cross-talk between AR and growth factor receptor signaling has an important role in mediation of androgen-regulated homeostasis, and disruption of this interaction is involved in the development of androgen-independent growth [58] [59] [60] . 
Table 1
Clinical and pathological characteristics of the patient cohort. 
